Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

€5m Initiative To Help EU Member States Cooperate On Trial Safety Assessments

Executive Summary

An EU funded project is to help national competent authorities cooperate on the safety assessment of clinical trials as required under the Clinical Trial Regulation.

You may also be interested in...



Sponsors Split Over Benefits Of EU Clinical Trials Regulation

A survey undertaken last year on the implementation of the EU Clinical Trials Regulation drew some positive feedback from study sponsors but also threw light on well-known concerns with the legislation. Some of the highlighted issues are being addressed on a priority basis.

EU Promises ‘Unifying’ Stakeholder Forum To Discuss Changes To Clinical Trial Landscape

The new workplan for the EU's initiative on accelerating clinical trials lays out the timelines for a set of “priority actions,” such as mapping the European clinical trial environment and establishing a consolidated process for more efficiently managing scientific advice on trials.

EU Finalizes Rules For Coordinated Trial Safety Assessment Under CTR

A new implementing regulation provides a legal basis for EU member states to cooperate on the assessment of trial-related safety reports linked to an active substance instead of the investigational medicinal product. 

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS147097

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel